However, whether the drug can truly be called "antisense" depends on some specifics--such as the ability to bind to targeted messenger RNA (mRNA) but avoid clinging to other proteins. Representatives ...

The earlier deal gave Sanofi a stake in Resalis Therapeutics, an Italian biotech that is advancing an antisense oligonucleotide that targets a noncoding RNA involved in obesity pathways.

They treated human PC3 prostate cancer cells with antisense phosphorothioate oligonucleotides (PS-ODNs) or with 2'-O-methyl RNA/DNA hybrid ODNs and examined changes in the expression profiles of over ...